Fig. 5From: High efficacy and safety of CD38 and BCMA bispecific CAR-T in relapsed or refractory multiple myelomaOne typical cases of patients treated with BCMA-CD38 CAR-T cells. SPEP (A) and FCM analysis (B) detecting CD269 and CD38 of Patient 10 before and after CAR-T infusionBack to article page